Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.62 |
| ▸ | KDR | P35968 | 13/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | STK25 | O00506 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | MUSK | O15146 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | PAK3 | O75914 | 1/20 | 0.52 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198176 | 0.87 | MET (0.56) | METKDRAXLMERTK | |
| SCHEMBL5485300 | 0.86 | MET (0.45) | METKDRJAK2AXL | |
| SCHEMBL4417454 | 0.85 | CD274 (0.46) | METKDRJAK2 | |
| SCHEMBL4417460 | 0.85 | CD274 (0.44) | METKDRJAK2MAP4K4ERBB2 | |
| SCHEMBL2197589 | 0.84 | MET (0.53) | METKDR | |
| SCHEMBL1790130 | 0.81 | MET (0.69) | METKDRPLK4STK25CIT | |
| SCHEMBL12424237 | 0.77 | MET (0.63) | METKDRPLK4STK25CIT | |
| SCHEMBL29693459 | 0.75 | MET (0.82) | METKDRPLK4STK25CIT | |
| SCHEMBL371849 | 0.75 | MET (0.82) | METKDRPLK4STK25CIT | |
| SCHEMBL371662 | 0.75 | MET (0.82) | METKDRPLK4STK25CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | MET 2/4885KDR 3/4885PLK4 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.